Overview

Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors

Status:
Completed
Trial end date:
2006-07-01
Target enrollment:
Participant gender:
Summary
Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be effective in treating malignant glioma.
Phase:
Phase 2
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc.
Teva Pharmaceutical Industries
Treatments:
Immunotoxins